BeiGene
BeiGene, Ltd. is a biotechnology company engaged in the development and commercialization of targeted and immuno-oncology therapeutics for cancer treatment. The company operates primarily in China and the United States, offering a range of commercial products including BRUKINSA for mantle cell lymphoma and Tislelizumab for classical Hodgkin's lymphoma. BeiGene's pipeline includes various clinical-stage drug candidates such as Zanubrutinib, an inhibitor for multiple lymphomas, and Pamiparib, a PARP inhibitor for solid tumors. The company also focuses on developing innovative treatments for diverse malignancies, such as acute myeloid leukemia, breast cancer, and non-small cell lung cancer. Its collaborations with multiple pharmaceutical companies enhance its capability to deliver affordable and accessible cancer therapies. Founded in 2010 and headquartered in Beijing, BeiGene aims to address significant unmet medical needs in oncology through its comprehensive portfolio of products and ongoing research initiatives.
Duo Oncology is focused on advancing treatment options for patients with pancreatic cancer and other challenging tumors through innovative nanoparticle technology. The company aims to redefine the treatment landscape by developing a novel monotherapy designed to penetrate established tumors more effectively. Collaborating closely with leading university scientists and medical oncologists, Duo Oncology leverages a network of established research organizations to expedite the development of its products. By addressing critical needs in immunotherapy and precision medicine, the company seeks to enhance patient outcomes and facilitate quicker recovery times for those facing hard-to-treat cancers.
Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2017. The company focuses on genetically programming mRNA to develop innovative therapies that enhance patient outcomes. Utilizing its mRNA programming technology, Strand Therapeutics creates gene therapies powered by synthetic biology, which include immunotherapies designed to stimulate cells to produce cancer-targeting proteins. This approach improves the immune system's ability to combat cancer by enabling precise control over the timing, location, and intensity of therapeutic protein expression. The technology leverages cell-type specific expression and responds to specific molecular signals, allowing for tailored therapeutic interventions.
Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on creating immune-based therapies for cancer and infectious diseases. Established in 2011 and headquartered in Winchester, Massachusetts, the company is engaged in the development of immunotherapies specifically targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the associated regulatory T cells found within the tumor microenvironment. Through its innovative platform, Boston Immune Technologies aims to advance treatment options for chronic infectious diseases and enhance the efficacy of cancer therapies.
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.